Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
Public Deposited- Creator
-
Dittmer, Dirk
- Affiliation: School of Medicine, Department of Microbiology and Immunology
-
Damania, Blossom
- Affiliation: School of Medicine, Department of Microbiology and Immunology
-
Sin, Sang-Hoon
- Affiliation: School of Medicine, Department of Microbiology and Immunology
-
Roy, Debasmita
- Affiliation: School of Medicine, Department of Microbiology and Immunology
- Abstract
- Rapamycin/Sirolimus™ leads to the regression of transplant- associated Kaposi sarcoma (KS). It also leads to disease stabilization in HIV-associated KS. Case reports and a wealth of preclinical studies support rapamycin’s efficacy also in AIDS associated lymphoma, such as primary effusion lymphoma (PEL). Rapamycin inhibits the mammalian target of rapamycin (mTOR) and papamycin derivatives are approved for the treatment of mantle cell lymphoma and other cancers. It is not universally effective against all solid tumors. Even within this group of clinically responsive cancers, there are exceptions of cases or cell models in which this drug or its derivatives (rapalogs) fail.
- Date of publication
- April 19, 2012
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Rights holder
- Dirk P Dittmer et al.; licensee BioMed Central Ltd.
- License
- Journal title
- Infectious Agents and Cancer
- Journal volume
- 7
- Journal issue
- Suppl 1
- Page start
- O9
- Language
- English
- Is the article or chapter peer-reviewed?
- Yes
- ISSN
- 1750-9378
- Bibliographic citation
- Infectious Agents and Cancer. 2012 Apr 19;7(Suppl 1):O9
- Publisher
- BioMed Central Ltd
- Access right
- Open Access
- Date uploaded
- August 23, 2012
Relations
- Parents:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
1750-9378-7-S1-O9.pdf | 2019-05-06 | Public | Download |
|
1750-9378-7-S1-O9.xml | 2019-05-06 | Public | Download |